On November 26, 2019 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, reported that Natalie Holles, President and Chief Operating Officer, will participate in the following investor conferences in December (Press release, Audentes Therapeutics, NOV 26, 2019, View Source [SID1234551756]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
31st Annual Piper Jaffray Healthcare Conference
Fireside Chat: Tuesday, December 3, 2019, at 10:00am ET
New York, New York
2nd Annual Evercore ISI HealthCONx
Panel: "Gene Therapy Manufacturing Powerhouses," Wednesday, December 4, 2019, at 8:45am ET
Boston, Massachusetts
To access the live webcast of the Piper Jaffray fireside chat, please visit the Events & Presentations page within the Investors + Media section of the Audentes website. Following the conference, a replay of the live webcast will be available on the Audentes website for approximately 30 days. There is no webcast available for the Gene Therapy Manufacutring Powerhouses panel at the Evercore ISI HealthCONx conference.